

Out. number: 194-00-77/23.07.2025

Treasury shares

Sofia, Bulgaria, July 23, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, **“Sopharma” AD** (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on July 22, 2025 the Company sold 11 000 (eleven thousand) repurchased own shares representing 0.01% of the share capital of the Company, at a total value of BGN 27 500.00 on the Bulgarian Stock Exchange, the average price per share was BGN 2.50.

The total number of treasury shares after this transaction is 8 365 727 representing 4.65% of the share capital of the Company.

/Signature/

Pelagia Viatcheva

Investor Relations Director

Information about the company

“Sopharma” AD

90 years of tradition and modernity - European GMP standards and quality, leader in market cap on the Bulgarian Stock Exchange, good corporate governance practices compliant.

Sopharma produces active pharmaceutical ingredients and medicinal products; conducts activities related to research, development and implementation in the field of phytochemistry, chemistry and pharmaceuticals, provides services related to production and auxiliary activities.

With 9 pharmaceutical plants in the country, including a unique ampoule factory in Bulgaria, the company produces more than 4 billion tablets, 9 million syrup forms, has marketing authorization for over 200 generic products, 15 traditional products, including 12 plant-based for which it uses more than 1500 tons of medicinal plants.

Sopharma has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma consistently invests in new technologies, innovations, research and sustainability. The company maintains a dialogue with all interested parties in the pharmaceutical industry and strives to contribute to improving the healthcare sector.

Sopharma Group

Sopharma Group is a vertically integrated health related business, that operates in important sectors such as medicinal products' manufacturing, hospital supplies, medicinal products' distribution, retail and many others.